Tempus is a data-driven precision medicine company bringing the power of data and artificial intelligence to healthcare. Tempus is a technology company advancing precision medicine through the ...

Tempus AI announced a collaboration with the Institute for Follicular Lymphoma Innovation. The goal of the collaboration is to advance targeted therapy development for follicular lymphoma by ...

Tempus is expected to releases its 2024 fiscal-year fourth-quarter earnings report after the market closes. Analysts estimate a loss per share of 20 cents and revenue of $203.12 million. Get 5 ...

Tempus AI is seeing strong growth as companies remain interested in the AI industry. Its annual revenue has jumped from $62.1 million in 2019 to over $531 million in the last financial year.

Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Refusing to slow down since the start of the new year, shares of Tempus AI (NASDAQ: TEM) have skyrocketed nearly 99% since Jan. 1. In light of the artificial intelligence (AI) stock's strong ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday ...

CHICAGO, February 18, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular ...